trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['biomarker', 'trastuzumab', 'breast']
destiny trial results are profound. but why? high false negatives of her2 ihc? false thinking about binary biomarkers? off target effect of the agent? trastuzumab deruxtecan in previously treated her2-low advanced breast cancer | #asco22 
Prostate cancer medical oncologist and physician-scientist, Kendrick Family Chair for Prostate Cancer Research, Cleveland Clinic. Posts are my own.